Coronavirus Thread: Worldwide Pandemic
- Thread starter 88m3
- Start date
88m3
Fast Money & Foreign Objects
ADevilYouKhow
Rhyme Reason
88m3
Fast Money & Foreign Objects
"This Is Tyranny": NYC Municipal Workers March On City Hall To Protest COVID Vaccine Mandate
fire all of them, look at the photos of this shyt
comments section is gold, I'll try and dig a few out tomorrow
fire all of them, look at the photos of this shyt
comments section is gold, I'll try and dig a few out tomorrow
Last edited:
Man On Fire
All Star
Evil VS Righteousness 
ADevilYouKhow
Rhyme Reason
All those clowns acting like they living off trust funds lmaoo"This Is Tyranny": NYC Municipal Workers March On City Hall To Protest COVID Vaccine Mandate
fire all of them, look at the photos of this shyt
comments section is gold, I'll try and dig a few out tomorrow
How is the vaccine going to kill black people if the USA didn't want sell mRNA technology to Africa?
Until today that is?
The USA was willing to sit on its advanced technology to preserve its technical advantage...but some how this is going to selectively kill off black people?
Don't believe me? LOOK!
Here’s Why Developing Countries Can Make mRNA Covid Vaccines
This makes NO sense. Anti-vaxxers taking ANOTHER L.
Plus, African countries WANT this.
apnews.com
BioNTech to work with Senegal, Rwanda to make mRNA vaccines
By CARLEY PETESCH
4-5 minutes
DAKAR, Senegal (AP) — Senegal and Rwanda have signed an agreement with German company BioNTech for the construction of its first start-to-finish factories to make messenger RNA vaccines in Africa.
BioNTech, which developed the Pfizer-BioNTech COVID-19 vaccine, said Tuesday that construction will start in mid-2022. It is working with the Institut Pasteur in Dakar, Senegal’s capital, and the Rwandan government, a statement said.
“State-of-the-art facilities like this will be life-savers and game-changers for Africa and could lead to millions of cutting-edge vaccines being made for Africans, by Africans in Africa,” said Matshidiso Moeti, the World Health Organization’s Regional Director for Africa. “This is also crucial for transferring knowledge and know-how, bringing in new jobs and skills and ultimately strengthening Africa’s health security.”
Ugur Sahin, the co-founder and CEO of BioNTech, said its goal is “to develop vaccines in the African Union and to establish sustainable vaccine production capabilities to jointly improve medical care in Africa.”
BioNTech had already agreed in August to work with Rwanda and Senegal to establish facilities in Africa capable of end-to-end manufacturing of mRNA-based vaccines, under license.
The novel mRNA process uses the genetic code for the spike protein of the coronavirus and is thought to trigger a better immune response than traditional vaccines. Scientists hope the technology, which is easier to scale up than traditional vaccine methods, might ultimately be used to make vaccines against other diseases, including malaria.
BioNTech said the facility in Africa will eventually produce about 50 million doses of the vaccine per year, with the capacity to increase.
BioNTech also said it is in discussions for expanding its partnership with the South African vaccine manufacturer Biovac, which is based in Cape Town. Biovac will assemble the vaccine using ingredients provided by BioNTech, a process called fill and finish. That production will begin in 2022 with a goal of reaching more than 100 million finished doses annually.
The BioNTech announcement was criticized by Rohit Malpani, an independent public health consultant in Paris, who previously worked for Doctors Without Borders.
“This is too little too late,” said Malpani. “Nothing should have stopped BioNTech from doing this a year ago when they were building factories in the U.S. and Germany. The fact that they sat on their hands and allowed this vaccine apartheid to proliferate and have left millions of people without vaccines shows that we cannot trust these companies.”
Malpani pointed out that the agreement is to produce the vaccine under license to BioNTech.
“This may expand production, but control over the vaccines still ultimately rests in BioNTech’s hands,” he said. “By the time these vaccines arrive, it will be far too late for millions of people. This does not ensure that countries will have access to vaccines or that they will be able to better respond to future pandemics.”
In contrast, Afrigen Biologics and Vaccines in Cape Town has established a lab and assembled scientists to produce an mRNA vaccine that is a replica of the Moderna vaccine, using information that is publicly available. With backing from the WHO, Afrigen plans to develop and produce an mRNA COVID-19 vaccine independent from Moderna or other big drug companies.
In July, Senegal had announced that the Institut Pasteur would manage a new manufacturing hub to produce vaccines including for COVID-19. The hub was estimated to cost $200 million and would be financed partly by funds from European and U.S. governments and institutions.
These vaccine manufacturing hubs in Africa will help reduce its dependence on imports, as the continent currently relies on imports for about 99% of its vaccine needs, according to the WHO. Africa and its 1.3 billion people remain the least-vaccinated region of the world against COVID-19, with just over 5% fully vaccinated, according to the Africa Centers for Disease Control and Prevention.
___
AP journalist Maria Cheng in London contributed.
reuters.com
BioNTech eyes construction start for African mRNA vaccine factory in mid-2022
October 26, 202110:48 AM EDTLast Updated a day ago
4 minutes
Test tubes are seen in front of a displayed Biontech logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic
FRANKFURT, Oct 26 (Reuters) - BioNTech (22UAy.DE) on Tuesday signed an agreement with the Rwandan government and Institut Pasteur de Dakar in Senegal on the construction of the first mRNA vaccine manufacturing facility in Africa starting in mid-2022, to help the continent ease health inequalities compared with other world regions.
BioNTech, which developed the western world's most widely used COVID-19 shots with partner Pfizer (PFE.N), will initially build a production line with an annual capacity of 50 million doses that could be used to make vaccines for such diseases as malaria and tuberculosis as well as for COVID-19, the company said in a statement and through a spokesperson.
This will be branched out into a wider production network making several hundred million mRNA vaccine doses per year with the goal of transferring ownership and know-how to partners on the continent, the biotech firm added.
"Our goal is to develop vaccines in the African Union and to establish sustainable vaccine production capabilities to jointly improve medical care in Africa," BioNTech Chief Executive Ugur Sahin said.
The partners may decide to make mRNA vaccines against other diseases such as malaria or tuberculosis depending on future development progress and medical needs, a company spokesperson said.
The project marks a longer-term attempt to avoid a repeat of healthcare inequalities brought to the fore by the coronavirus pandemic.
"Today's agreements are key steps toward producing vaccines end-to-end in Africa,” Rwandan Health Minister Daniel Ngamije said during the signing ceremony in the capital Kigali, adding that the goal was to include the continent in the "networks of science, innovation and production.”
Ngamije's enthusiasm echoed in the words of Senegal's foreign affairs minister.
"What was thought to be a dream is being realized,” said Aïssata Tall Sall, Senegal's foreign affairs minister.
EU foreign policy chief Josep Borrell said the production "for Africa in Africa" was the "only viable long-term solution to any pandemic."
Speaking at a media briefing in Kigali, European Union Commissioner for International Partnerships Jutta Urpilainen said that the initial site would be built in Rwanda.
The announcements add details to plans - unveiled by BioNTech in August - to build malaria and tuberculosis vaccine production sites in Rwanda and Senegal, at the time narrowing its search for African locations. read more
BioNTech added on Tuesday that Rwanda and Senegal's Institut Pasteur de Dakar would build facilities for final production steps and bottling in a process known as fill and finish, in parallel with BioNTech's construction activities.
The German group said it was also in talks with South Africa’s Biovac Institute about expansion of their current manufacturing partnership.
BioNTech and Pfizer in July struck a deal for Biovac to fill and finish over 100 million doses a year of their COVID-19 vaccine for Africa, based on imported active substance.
Also in July, it said it would seek to develop a malaria vaccine, eyeing production in Africa. read more
Reporting by Ludwig Burger; Additional reporting by Clement Uwiringiyimana in Kigali; Editing by Riham Alkousaa, Bernadette Baum, Steve Orlopfsky and Mark Porter
Our Standards: The Thomson Reuters Trust Principles.
Until today that is?
The USA was willing to sit on its advanced technology to preserve its technical advantage...but some how this is going to selectively kill off black people?
Don't believe me? LOOK!
Here’s Why Developing Countries Can Make mRNA Covid Vaccines
This makes NO sense. Anti-vaxxers taking ANOTHER L.
Plus, African countries WANT this.
apnews.com
BioNTech to work with Senegal, Rwanda to make mRNA vaccines
By CARLEY PETESCH
4-5 minutes
DAKAR, Senegal (AP) — Senegal and Rwanda have signed an agreement with German company BioNTech for the construction of its first start-to-finish factories to make messenger RNA vaccines in Africa.
BioNTech, which developed the Pfizer-BioNTech COVID-19 vaccine, said Tuesday that construction will start in mid-2022. It is working with the Institut Pasteur in Dakar, Senegal’s capital, and the Rwandan government, a statement said.
“State-of-the-art facilities like this will be life-savers and game-changers for Africa and could lead to millions of cutting-edge vaccines being made for Africans, by Africans in Africa,” said Matshidiso Moeti, the World Health Organization’s Regional Director for Africa. “This is also crucial for transferring knowledge and know-how, bringing in new jobs and skills and ultimately strengthening Africa’s health security.”
Ugur Sahin, the co-founder and CEO of BioNTech, said its goal is “to develop vaccines in the African Union and to establish sustainable vaccine production capabilities to jointly improve medical care in Africa.”
BioNTech had already agreed in August to work with Rwanda and Senegal to establish facilities in Africa capable of end-to-end manufacturing of mRNA-based vaccines, under license.
The novel mRNA process uses the genetic code for the spike protein of the coronavirus and is thought to trigger a better immune response than traditional vaccines. Scientists hope the technology, which is easier to scale up than traditional vaccine methods, might ultimately be used to make vaccines against other diseases, including malaria.
BioNTech said the facility in Africa will eventually produce about 50 million doses of the vaccine per year, with the capacity to increase.
BioNTech also said it is in discussions for expanding its partnership with the South African vaccine manufacturer Biovac, which is based in Cape Town. Biovac will assemble the vaccine using ingredients provided by BioNTech, a process called fill and finish. That production will begin in 2022 with a goal of reaching more than 100 million finished doses annually.
The BioNTech announcement was criticized by Rohit Malpani, an independent public health consultant in Paris, who previously worked for Doctors Without Borders.
“This is too little too late,” said Malpani. “Nothing should have stopped BioNTech from doing this a year ago when they were building factories in the U.S. and Germany. The fact that they sat on their hands and allowed this vaccine apartheid to proliferate and have left millions of people without vaccines shows that we cannot trust these companies.”
Malpani pointed out that the agreement is to produce the vaccine under license to BioNTech.
“This may expand production, but control over the vaccines still ultimately rests in BioNTech’s hands,” he said. “By the time these vaccines arrive, it will be far too late for millions of people. This does not ensure that countries will have access to vaccines or that they will be able to better respond to future pandemics.”
In contrast, Afrigen Biologics and Vaccines in Cape Town has established a lab and assembled scientists to produce an mRNA vaccine that is a replica of the Moderna vaccine, using information that is publicly available. With backing from the WHO, Afrigen plans to develop and produce an mRNA COVID-19 vaccine independent from Moderna or other big drug companies.
In July, Senegal had announced that the Institut Pasteur would manage a new manufacturing hub to produce vaccines including for COVID-19. The hub was estimated to cost $200 million and would be financed partly by funds from European and U.S. governments and institutions.
These vaccine manufacturing hubs in Africa will help reduce its dependence on imports, as the continent currently relies on imports for about 99% of its vaccine needs, according to the WHO. Africa and its 1.3 billion people remain the least-vaccinated region of the world against COVID-19, with just over 5% fully vaccinated, according to the Africa Centers for Disease Control and Prevention.
___
AP journalist Maria Cheng in London contributed.
reuters.com
BioNTech eyes construction start for African mRNA vaccine factory in mid-2022
October 26, 202110:48 AM EDTLast Updated a day ago
4 minutes
Test tubes are seen in front of a displayed Biontech logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic
FRANKFURT, Oct 26 (Reuters) - BioNTech (22UAy.DE) on Tuesday signed an agreement with the Rwandan government and Institut Pasteur de Dakar in Senegal on the construction of the first mRNA vaccine manufacturing facility in Africa starting in mid-2022, to help the continent ease health inequalities compared with other world regions.
BioNTech, which developed the western world's most widely used COVID-19 shots with partner Pfizer (PFE.N), will initially build a production line with an annual capacity of 50 million doses that could be used to make vaccines for such diseases as malaria and tuberculosis as well as for COVID-19, the company said in a statement and through a spokesperson.
This will be branched out into a wider production network making several hundred million mRNA vaccine doses per year with the goal of transferring ownership and know-how to partners on the continent, the biotech firm added.
"Our goal is to develop vaccines in the African Union and to establish sustainable vaccine production capabilities to jointly improve medical care in Africa," BioNTech Chief Executive Ugur Sahin said.
The partners may decide to make mRNA vaccines against other diseases such as malaria or tuberculosis depending on future development progress and medical needs, a company spokesperson said.
The project marks a longer-term attempt to avoid a repeat of healthcare inequalities brought to the fore by the coronavirus pandemic.
"Today's agreements are key steps toward producing vaccines end-to-end in Africa,” Rwandan Health Minister Daniel Ngamije said during the signing ceremony in the capital Kigali, adding that the goal was to include the continent in the "networks of science, innovation and production.”
Ngamije's enthusiasm echoed in the words of Senegal's foreign affairs minister.
"What was thought to be a dream is being realized,” said Aïssata Tall Sall, Senegal's foreign affairs minister.
EU foreign policy chief Josep Borrell said the production "for Africa in Africa" was the "only viable long-term solution to any pandemic."
Speaking at a media briefing in Kigali, European Union Commissioner for International Partnerships Jutta Urpilainen said that the initial site would be built in Rwanda.
The announcements add details to plans - unveiled by BioNTech in August - to build malaria and tuberculosis vaccine production sites in Rwanda and Senegal, at the time narrowing its search for African locations. read more
BioNTech added on Tuesday that Rwanda and Senegal's Institut Pasteur de Dakar would build facilities for final production steps and bottling in a process known as fill and finish, in parallel with BioNTech's construction activities.
The German group said it was also in talks with South Africa’s Biovac Institute about expansion of their current manufacturing partnership.
BioNTech and Pfizer in July struck a deal for Biovac to fill and finish over 100 million doses a year of their COVID-19 vaccine for Africa, based on imported active substance.
Also in July, it said it would seek to develop a malaria vaccine, eyeing production in Africa. read more
Reporting by Ludwig Burger; Additional reporting by Clement Uwiringiyimana in Kigali; Editing by Riham Alkousaa, Bernadette Baum, Steve Orlopfsky and Mark Porter
Our Standards: The Thomson Reuters Trust Principles.
88m3
Fast Money & Foreign Objects
FDNY: 1 In 5 Ambulances, Fire Companies Could Be Offline Monday As NYC Workers Fight Vaccine Mandate
need to be fired and never allowed to work for the city/state again
need to be fired and never allowed to work for the city/state again
